Mesa Laboratories (MLAB) AI Stock Analysis

• Market Cap: $365.35M
• Dividend Yield: 0.96%
• Average Volume (3M): 168.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: 8.33%
• EPS Growth: 99.75%
• Country: US
• Employees: 736
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 2.32
• Shares Outstanding: 5,501,454
• 10 Day Avg. Volume: 279,013
• 30 Day Avg. Volume: 168,642
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.88
• Enterprise Value/Revenue: 2.83
• Enterprise Value/Gross Profit: 4.70
• Enterprise Value/Ebitda: 15.38
• 1Y Price Target: $82.00
• Price Target Upside: 27.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 49 Neutral
• Price Target: $69.00 ▲(7.58% Upside)

Mesa Laboratories' stock score is primarily impacted by its mixed financial performance, with strong revenue growth but ongoing profitability challenges. The technical analysis indicates a bearish trend, and the valuation reflects unprofitability. However, the strategic corporate event positively influences the score by demonstrating effective financial management.

Mesa Laboratories Business Overview & Revenue Model

Company Description

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

How the Company Makes Money

Mesa Laboratories generates revenue through the sale of its specialized monitoring and control instruments, as well as through its services related to biopharmaceutical development and regulatory compliance. Key revenue streams include the direct sale of products such as data loggers, sterilization indicators, and related software solutions. The company also earns income from service contracts and consulting related to compliance and quality assurance. Significant partnerships with healthcare facilities, pharmaceutical companies, and biotechnology firms enhance its market reach and contribute to its earnings, as these clients rely on Mesa's products to ensure regulatory compliance and maintain quality standards in their operations.

Mesa Laboratories Financial Statement Overview

Summary

Mesa Laboratories shows strong revenue growth and gross margins, but profitability is a concern with negative net margins and ROE. Improved leverage management is noted, but cash flow challenges persist with declining free cash flow growth.

Income Statement

Mesa Laboratories shows a mixed performance in its income statement. The TTM gross profit margin is strong at 62.1%, indicating efficient cost management. However, the net profit margin is negative, reflecting ongoing profitability challenges. Revenue growth is robust at 57% TTM, but the negative EBIT and EBITDA margins in previous years highlight operational inefficiencies.

Balance Sheet

The balance sheet presents a moderate financial position. The debt-to-equity ratio has improved to 0.67 TTM from higher levels, suggesting better leverage management. However, the negative return on equity indicates that the company is not generating positive returns for shareholders. The equity ratio remains stable, reflecting a balanced asset structure.

Cash Flow

Cash flow analysis reveals some strengths, with a positive operating cash flow to net income ratio of 0.26 TTM, indicating effective cash generation relative to earnings. However, the free cash flow growth is negative, which could impact future investments. The free cash flow to net income ratio is strong, suggesting good cash conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	242.35M	240.98M	216.19M	219.08M	184.34M	133.94M
Gross Profit	146.12M	150.87M	133.25M	133.69M	109.09M	87.01M
EBITDA	44.66M	42.35M	-238.38M	36.45M	29.77M	12.36M
Net Income	-620.00K	-1.97M	-254.25M	930.00K	1.87M	3.27M
Balance Sheet
Total Assets	435.74M	433.35M	446.80M	661.83M	707.37M	600.15M
Cash, Cash Equivalents and Short-Term Investments	21.28M	27.32M	28.21M	32.91M	49.35M	263.87M
Total Debt	184.94M	181.47M	231.30M	170.27M	221.13M	146.70M
Total Liabilities	263.25M	273.52M	301.40M	268.35M	313.57M	193.92M
Stockholders Equity	172.50M	159.83M	145.39M	393.48M	393.80M	406.23M
Cash Flow
Free Cash Flow	33.65M	42.31M	41.57M	23.44M	34.79M	35.08M
Operating Cash Flow	38.27M	46.81M	44.13M	27.98M	39.22M	37.07M
Investing Cash Flow	-4.62M	-4.50M	-81.31M	-9.49M	-305.23M	-1.99M
Financing Cash Flow	-43.83M	-44.51M	32.84M	-33.33M	52.58M	146.23M

Mesa Laboratories Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 64.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLAB, the sentiment is Negative. The current price of 64.14 is below the 20-day moving average (MA) of 65.64, below the 50-day MA of 68.24, and below the 200-day MA of 107.69, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 44.75 is Neutral, neither overbought nor oversold. The STOCH value of 43.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLAB.

Mesa Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYTS	77 Outperform	714.07M	29.54	10.57%	0.84%	22.09%	-5.26%
BELFA	76 Outperform	1.75B	29.28	12.60%	0.20%	6.08%	-23.93%
DAKT	68 Neutral	1.03B	4,793.18	-3.72%	―	-7.67%	7.66%
VPG	67 Neutral	430.11M	-330.08	3.08%	―	-11.47%	-106.18%
MLAB	49 Neutral	$365.35M	―	-0.38%	0.96%	8.33%	99.75%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

Mesa Laboratories Corporate Events

Mesa Laboratories Holds Annual Shareholder Meeting

On August 22, 2025, Mesa Laboratories held its annual meeting of shareholders where 5,203,377 shares were represented. During the meeting, the election of directors was confirmed, with John J. Sullivan, Gary M. Owens, Jenny S. Alltoft, Shannon M. Hall, Shiraz S. Ladiwala, R. Tony Tripeny, and Mark C. Capone elected to the board for a one-year term. The board also appointed members to its committees. Additionally, the shareholders ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. The compensation of the company’s named executive officers was approved on a non-binding basis, and an amendment to the 2021 Equity Incentive Plan was also approved.

Mesa Laboratories Draws $97M for Convertible Notes Settlement

On August 12, 2025, Mesa Laboratories, Inc. drew $97 million from its existing Credit Facility to fund the settlement of its outstanding convertible notes that matured on August 15, 2025. This strategic financial move, part of a plan announced in April 2024, aims to optimize Mesa’s capital structure and reduce potential shareholder dilution. The company expects to benefit from future interest rate reductions and plans to make significant principal payments in fiscal year 2026, demonstrating its commitment to prudent financial management and shareholder value.